Sequence driven interaction of amino acids in de-novo designed peptides determines c-Myc G-quadruplex unfolding inducing apoptosis in cancer cells
c-MYC proto-oncogene harbors a putative G-quadruplex structure (Pu27) at the NHEIII1 domain, which can shuffle between transcriptional inhibitor quadruplex and transcriptionally active duplex. In cancer cells this quadruplex destabilization is preferred and NHEIII1 domain assume a duplex topology th...
Saved in:
Published in | Biochimica et biophysica acta. General subjects Vol. 1867; no. 2; p. 130267 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.02.2023
|
Subjects | |
Online Access | Get full text |
ISSN | 0304-4165 1872-8006 1872-8006 |
DOI | 10.1016/j.bbagen.2022.130267 |
Cover
Summary: | c-MYC proto-oncogene harbors a putative G-quadruplex structure (Pu27) at the NHEIII1 domain, which can shuffle between transcriptional inhibitor quadruplex and transcriptionally active duplex. In cancer cells this quadruplex destabilization is preferred and NHEIII1 domain assume a duplex topology thereby inducing c-MYC overexpression and tumorigenesis. Hence, the c-MYC quadruplex acts as an excellent target for anti-cancer therapy. Though researcher have tried to develop G-quadruplex targeted small molecules, work with G-quadruplex targeting peptides is very limited. Here we present a peptide that can bind to c-MYC quadruplex, destabilize the tetrad core, and permit the formation of a substantially different structure from the quartet core seen in the canonical G-quadruplexes. Such conformation potentially acted as a roadblock for transcription factors thereby reducing cMYC expression. This event sensitizes the cancer cell to activate apoptotic cascade via the c-MYC-VEGF-A-BCL2 axis. This study provides a detailed insight into the peptide-quadruplex interface that encourages better pharmacophore design to target dynamic quadruplex structure. We believe that our results will contribute to the development, characterization, and optimization of G-quadruplex binding peptides for potential clinical application.
Schematic representation of the mode of action of CD23 peptide. [Display omitted]
•Peptides act as an excellent ligands to arrest G-quadruplex structures. Its high specificity is coupled with low toxicity•c-Myc G-quadruplex targeted therapy can be manipulated to develop gene directed anticancer therapeutics.•G-quadruplex destabilization can be exploited to develop anticancer therapy.•There is no drug targeting c-Myc oncogene. NHE-III1 element has been shown to be a fantastic target for c-Myc suppression. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0304-4165 1872-8006 1872-8006 |
DOI: | 10.1016/j.bbagen.2022.130267 |